Skip to main content
CTOS 2023 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Session 4: Medical and Pediatric Oncology Trials

Thursday, November 2, 2023
4:00 PM – 5:30 PM  

Presentations:

  • 4:00 PM – 5:30 PM  
    A PHASE II STUDY OF CABOZANTINIB AND TEMOZOLOMIDE IN PATIENTS WITH UNRESECTABLE OR METASTATIC LEIOMYOSARCOMA AND OTHER SOFT TISSUE SARCOMAS

    Author: Mark Agulnik, MD (he/him/his) – City of Hope, Department of Medical Oncology & Therapeutics Research

    Co-Author: Varun Monga, MBBS (he/him/his) – UCSF Helen Diller Family Comprehensive Cancer Center

    Co-Author: John Charlson, MD (he/him/his) – Medical College of Wisconsin

    Co-Author: Brian Schulte, MD – UCSF Helen Diller Family Comprehensive Cancer Center

    Co-Author: Mohammed Milhem, MBBS – University of Iowa, Holden Comprehensive Cancer Center

    Co-Author: Paul Frankel, MD – City of Hope Comprehensive Cancer Center

    Co-Author: Brian Van Tine, MD – Washington University in St. Louis

    Co-Author: Mia C. Weiss, MD – Washington University School of Medicine

    Co-Author: Angela Hirbe, MD,PHD – Washington University in St. Louis

    Co-Author: Seth Pollack, MD – Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Co-Author: Pedro Viveiros, MD – Northwestern University

    Co-Author: Scott Okuno, M.D. – Mayo Clinic

    Co-Author: Steven Attia, D.O. – Mayo Clinic

    Co-Author: Brittany Siontis, MD – Mayo Clinic

    Co-Author: Steven Robinson, MBBS – Mayo Clinic

    Co-Author: Janet Yoon, MD – City of Hope Comprehensive Cancer Center

  • 4:00 PM – 5:30 PM  
    A PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA

    Author: Patrick Schöffski, MD, MPH – Department of General Medical Oncology, University Hospitals Leuven, and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium

    Co-Author: Patricia LoRusso, MD – Yale University School of Medicine, Yale Cancer Center

    Co-Author: Noboru Yamamoto, MD – Department of Experimental Therapeutics, National Cancer Center Hospital

    Co-Author: Iwona Lugowska, MD – Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology

    Co-Author: Victor Moreno, PhD – START Madrid-FJD, Fundación Jiménez Díaz

    Co-Author: Ulrich M. Lauer, MD – Department of Medical Oncology & Pneumology and Tübingen Early Phase Clinical Trials Unit, University Hospital Tübingen

    Co-Author: Chenxiao Hu, MD – Boehringer Ingelheim Pharmaceuticals Inc.

    Co-Author: Sara Durland-Busbice, MD – Boehringer Ingelheim Pharmaceuticals Inc.

    Co-Author: Girish Jayadeva, MD – Boehringer Ingelheim Pharmaceuticals Inc.

    Co-Author: Mehdi Lahmar, MD (he/him/his) – Boehringer Ingelheim International GmbH

    Co-Author: Mrinal Gounder, MD – Memorial Sloan Kettering Cancer Center

  • 4:00 PM – 5:30 PM  
    MILADEMETAN VS. TRABECTEDIN IN PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: RESULTS FROM THE PHASE 3 MANTRA STUDY

    Author: Roberta Sanfilippo, MD – Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

    Co-Author: Robin L. Jones, BSc, MB BS, MRCP, MD – Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

    Co-Author: Scott M. Schuetze, MD, PhD – University of Michigan

    Co-Author: Ana Sebio, MD, PhD (she/her/hers) – Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

    Co-Author: Rosa Álvarez Álvarez, PhD, MD – Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

    Co-Author: Nam Bui, MD – Stanford University

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

    Co-Author: Sant P. Chawla, MD, FRACP (he/him/his) – Sarcoma Oncology Center

    Co-Author: Tom Wei-Wu Chen, PhD – National Taiwan University Hospital

    Co-Author: Daniel Pink, MD – Helios Hospital Bad Saarow, Sarcoma Centre Berlin-Brandenburg, Department of Hematology, Oncology and Palliative Care

    Co-Author: Axel Le Cesne, MD – Gustave Roussy Institute

    Co-Author: Antoine Italiano, MD,PhD – Institut Bergonié

    Co-Author: Bruno Vincenzi, MD, PhD – Università Campus Biomedico di Roma, Roma, Italy

    Co-Author: Jin-Hee Ahn, MD, PhD – Asan Medical Centre

    Co-Author: Gabriel Tinoco, MD – Ohio State University

    Co-Author: Seth Pollack, MD – Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Co-Author: Herbert Ho Fung Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine) (he/him/his) – The Chinese University of Hong Kong

    Co-Author: Ivane Kiladze, MD, PhD (he/him/his) – Caucasus Medical Centre

    Co-Author: Giovanni Grignani, MD – Candiolo Cancer Institute, FPO – IRCCS

    Co-Author: Thibaud Valentin, MD (he/him/his) – Oncopole Claudius Regaud

    Co-Author: Justine Gantzer, MD (she/her/hers) – Institut de cancérologie Strasbourg Europe

    Co-Author: Albiruni Ryan Abdul Razak, MB BCh, BM BCh – Princess Margaret Cancer Center

    Co-Author: Javier Martin-Broto, MD, PhD (he/him/his) – Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology

    Co-Author: Shreyaskumar Patel, MD (he/him/his) – The University of Texas MD Anderson Cancer Center

    Co-Author: Naisargee Shah, PhD – Rain Oncology Inc.

    Co-Author: Robert C. Doebele, MD, PhD (he/him/his) – Rain Oncology

    Co-Author: Feng Xu, BS – Rain Oncology Inc.

    Co-Author: Richard Bryce, MD – Rain Oncology Inc.

    Co-Author: Gary K. Schwartz, MD – Herbert Irving Comprehensive Cancer Center at Columbia University School of Medicine

    Co-Author: Mrinal Gounder, MD – Memorial Sloan Kettering Cancer Center

  • 4:00 PM – 5:30 PM  
    PRELIMINARY RESULTS FROM A PHASE 1 STUDY OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS

    Author: Andy Livingston, MD, MS (he/him/his) – The University of Texas MD Anderson Cancer Center

    Co-Author: Gregory M. Cote, MD, PhD (he/him/his) – Mass General Cancer Center

    Co-Author: Jean-Yves Blay, MD, PhD – Centre Léon-Bérard

    Co-Author: Jonathan Trent, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami

    Co-Author: Claudia Valverde, MD – Vall D’Hebron University Hospital

    Co-Author: Mark Agulnik, MD (he/him/his) – City of Hope, Department of Medical Oncology & Therapeutics Research

    Co-Author: Mrinal Gounder, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Axel Le Cesne, MD – Gustave Roussy Institute

    Co-Author: Meredith McKean, MPH, MD – Sarah Cannon Research Institute

    Co-Author: Michael J. Wagner, MD – University of Washington/Fred Hutch/Seattle Cancer Care Alliance

    Co-Author: Silvia Stacchiotti, MD (she/her/hers) – Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Co-Author: Samuel V. Agresta, MD – Foghorn Therapeutics

    Co-Author: Sarah Reilly, MD, MPH – Foghorn Therapeutics

    Co-Author: Kathleen Healy, n/a – Foghorn Therapeutics

    Co-Author: Denice Hickman, Registered Nurse/BSN (she/her/hers) – Foghorn Therapeutics

    Co-Author: Mike Collins, PhD (he/him/his) – Foghorn Therapeutics

    Co-Author: Scott Innis, MS – Foghorn Therapeutics

    Co-Author: Alexandra R. Ballesteros-Perez, PhD (she/her/hers) – Certara

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

  • 4:00 PM – 5:30 PM  
    A FIRST-IN-HUMAN STUDY OF CDK9 INHIBITOR KB-0742 DEMONSTRATES PRELIMINARY EVIDENCE OF CLINICAL ACTIVITY IN TRANSCRIPTIONALLY ADDICTED SARCOMAS

    Author: Brian Andrew Van Tine, MD, PhD (he/him/his) – Washington University School of Medicine

    Co-Author: Berkley E. Gryder, PhD – Case Western Reserve University

    Co-Author: Jonathan Nakashima, PhD – Certis Oncology

    Co-Author: Monica M. Mita, MD – Cedars-Sinai, Samuel Oschin Cancer Center

    Co-Author: Alain C. Mita, MD – Cedars-Sinai, Samuel Oschin Cancer Center

    Co-Author: Noah Federman, MD – David Geffen School of Medicine, University of California, Los Angeles

    Co-Author: Drew W. Rasco, MD – START Center for Cancer Care

    Co-Author: David Spigel, MD – Sarah Cannon Research Institute at Tennessee Oncology

    Co-Author: Jia Luo, MD – Dana-Farber Cancer Institute

    Co-Author: Diana H. Chin, BS – Case Western Reserve University

    Co-Author: Gregory M. Cote, MD, PhD (he/him/his) – Mass General Cancer Center

    Co-Author: Richard E. Cutler, Jr., PhD (he/him/his) – Kronos Bio

    Co-Author: Pavan Kumar, PhD – Kronos Bio

    Co-Author: Tressa R. Hood, MS (she/her/hers) – Kronos Bio

    Co-Author: Luis A. Carvajal, PhD – Kronos Bio

    Co-Author: Crystal J. MacKenzie, BS – Kronos Bio

    Co-Author: Charles Y. Lin, PhD – Kronos Bio

    Co-Author: Jorge F. DiMartino, MD, PhD (he/him/his) – Kronos Bio

    Co-Author: Elizabeth A. Olek, DO, MPH – Kronos Bio

    Co-Author: Miguel A. Villalona-Calero, MD (he/him/his) – City of Hope National Medical Center

  • 4:00 PM – 5:30 PM  
    SAFETY AND EFFICACY UPDATES FROM A PHASE 1 STUDY OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR

    Author: Hans Gelderblom, MD, PhD (he/him/his) – Leiden University Medical Center

    Co-Author: Albiruni Ryan Abdul Razak, MB BCh, BM BCh – Princess Margaret Cancer Center

    Co-Author: Javier Martin-Broto, MD, PhD (he/him/his) – Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology

    Co-Author: Breelyn A. Wilky, MD – University of Colorado Cancer Center

    Co-Author: Piotr Rutkowski, MD, PhD – Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma

    Co-Author: Nicholas Bernthal, MD – University of California Los Angeles

    Co-Author: Supraja Narasimhan, MS, PhD – Deciphera Pharmaceuticals, LLC

    Co-Author: Maitreyi G. Sharma, MD (she/her/hers) – Deciphera Pharmaceuticals, LLC

    Co-Author: Rodrigo Ruiz-Soto, MD/MSc (he/him/his) – Deciphera Pharmaceuticals, LLC

    Co-Author: Matthew L. Sherman, MD – Deciphera Pharmaceuticals, LLC

    Co-Author: William D. Tap, MD – Memorial Sloan Kettering Cancer Center

  • 4:00 PM – 5:30 PM  
    A PHASE 4, MULTICENTER, GLOBAL CLINICAL TRIAL TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB

    Co-Author: Jayesh Desai, MBBS FRACP – Peter MacCallum Cancer Centre

    Co-Author: Andrew J. Wagner, MD, PhD – Dana-Farber Cancer Institute

    Co-Author: Irene Carrasco Garcia, MD – Virgen del Rocio University Hospital

    Co-Author: Marilena Cesari, MD – Rizzoli Orthopedic Institute

    Co-Author: Michael Gordon, MD – HonorHealth Research Institute

    Co-Author: Chia-Chi Lin, MD, PhD – National Taiwan University Hospital

    Co-Author: Zsuzsanna Papai, MD – Semmelweis University

    Co-Author: Christopher W. Ryan, MD – OHSU Knight Cancer Institute, South Waterfront

    Co-Author: William D. Tap, MD – Memorial Sloan Kettering Cancer Center

    Co-Author: Jonathan Trent, MD, PhD – Sylvester Comprehensive Cancer Center, University of Miami

    Co-Author: Hans Gelderblom, MD, PhD (he/him/his) – Leiden University Medical Center

    Co-Author: Peter Grimison, MD, PhD – Chris O'Brien Lifehouse

    Co-Author: Antonio López Pousa, MD – Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

    Co-Author: Brian Andrew Van Tine, MD, PhD (he/him/his) – Washington University School of Medicine

    Co-Author: Maria Rubinacci, MS, MBE (she/her/hers) – Daiichi Sankyo, Inc.

    Co-Author: Kristen Tecson, PhD – Daiichi Sankyo, Inc.

    Co-Author: Margaret Wooddell, PhD, MBA – Daiichi Sankyo, Inc.

    Author: Silvia Stacchiotti, MD (she/her/hers) – Department of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • 4:00 PM – 5:30 PM  
    INTERNATIONAL RANDOMISED TRIAL OF THE ADDITION OF ZOLEDRONIC ACID TO CONSOLIDATION CHEMOTHERAPY IN NEWLY DIAGNOSED EWING SARCOMA PATIENTS RESULTS OF THE SECOND RANDOMISATION EE2012 TRIAL

    Author: Bernadette Brennan, BSC MBChB MD – Royal Manchester Children's Hospital

    Co-Author: Laura Kirton, Bsc – Cancer Research UK Clinical Trials Unit (CRCTU)

    Co-Author: Françoise Françoise, PhD – UMR_S 1307 Center for Research in Cancer and Integrated Immunology

    Co-Author: Perrine Marec-Berard, MD (she/her/hers) – Centre Léon Bérard

    Co-Author: Javier Martin-Broto, MD, PhD (he/him/his) – Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz and Villalba General Hospital, Madrid, Spain; Medical Oncology

    Co-Author: Hans Gelderblom, MD, PhD (he/him/his) – Leiden University Medical Center

    Co-Author: Sandra J. Strauss, MD PhD FRCP (she/her/hers) – UCL Cancer Institute

    Co-Author: Nathalie Gaspar, PhD MD (she/her/hers) – Gustave Roussy cancer campus

    Co-Author: Jennifer Anderton, Bsc PhD (she/her/hers) – Cancer Research UK Clinical Trials Unit (CRCTU)

    Co-Author: Ana Sastre, MD – La Paz Hospital

    Co-Author: Valerie Laurence, MD PhD – Institute Curie

    Co-Author: Cormac Owens, MB FRCPI – 11. Our Lady’s Children’s Hospital, Dublin, Ireland

    Co-Author: Piers Gaunt, MSc (he/him/his) – Cancer Research UK Clinical Trials Unit (CRCTU)

    Co-Author: Keith Wheatley, BSc PhD – Cancer Research UK Clinical Trials Unit (CRCTU)